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Selective inhibition of amino-terminal methionine processing by
TNP-470 and ovalicin in endothelial cells
Benjamin E Turk1,2, Eric C Griffith1,3, Susan Wolf2, Klaus Biemann2,
Yie-Hwa Chang4 and Jun O Liu1,2,3
Background: The angiogenesis inhibitors TNP-470 and ovalicin potently
suppress endothelial cell growth. Both drugs also specifically inhibit methionine
aminopeptidase 2 (MetAP2) in vitro. Inhibition of MetAP2 and changes in
initiator methionine removal in drug-treated endothelial cells have not been
demonstrated, however.
Results: Concentrations of TNP-470 sufficient to inactivate MetAP2 in intact
endothelial cells were comparable to those that inhibited cell proliferation,
suggesting that MetAP2 inhibition by TNP-470 underlies the ability of the drug to
inhibit cell growth. Both drug-sensitive and drug-insensitive cell lines express
MetAP1 and MetAP2, indicating that drug sensitivity in mammalian cells is not
simply due to the absence of compensating MetAP activity. With a single
exception, detectable protein N-myristoylation is unaffected in sensitive endothelial
cells treated with TNP-470, so MetAP1 activity can generally compensate when
MetAP2 is inactive. Analysis of total protein extracts from cells pulse-labeled with
[35S]-methionine following TNP-470 treatment revealed changes in the migration
of several newly synthesized proteins. Two of these proteins were identified as
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and cyclophilin A.
Purification and amino-terminal sequencing of GAPDH from TNP-470-treated cells
revealed partial retention of its initiator methionine, indicating that methionine
removal from some, but not all, proteins is affected by MetAP2 inactivation.
Conclusions: Amino-terminal processing defects occur in cells treated with
TNP-470, indicating that inhibition of MetAP2 by the drug occurs in intact cells.
This work renders plausible a mechanism for growth inhibition by TNP-470 as a
consequence of initiator methionine retention, leading to the inactivation of as
yet unidentified proteins essential for endothelial cell growth.
Introduction
TNP-470, a synthetic derivative of the fungal metabolite
fumagillin, is a member of a novel class of anticancer drugs
that act by inhibiting angiogenesis, the growth of new
blood vessels, which is an event required for tumor pro-
gression [1–4]. The compound potently inhibits the
growth of primary tumors and metastases in experimental
animals and is currently in phase II clinical trials to treat a
variety of cancers, including Kaposi’s sarcoma, prostate
cancer, cervical carcinoma, glioblastoma, pancreatic cancer
and renal cancer [5]. TNP-470 inhibits the growth of
endothelial cells and vascular smooth muscle cells in
culture at picomolar concentrations. Much higher concen-
trations of the drug are required to substantially inhibit
the growth of tumor cells in culture, however, suggesting
that the effects of the drug in vivo are likely to be medi-
ated by inhibition of angiogenesis [3,6,7].
TNP-470, fumagillin and the structurally related natural
product ovalicin specifically and covalently inactivate
methionine aminopeptidase 2 (MetAP2), one of two
enzymes responsible for the cotranslational removal of the
initiator methionine residue in eukaryotes [8,9]. The
ability of fumagillin and ovalicin analogs to inhibit
endothelial cell growth correlates strongly with their
ability to inhibit MetAP2 activity, suggesting that inhibi-
tion of the enzyme underlies the growth-arresting effects
of these drugs [8]. The mechanism by which inhibition of
MetAP2 might lead to growth inhibition is not clear,
however. Amino-terminal processing is essential for the
activity of certain proteins that regulate cell growth.
Removal of the initiator methionine residue is a prerequi-
site for post-translational modifications to the amino ter-
minus, such as myristoylation and acetylation, which can
be required for the proper localization and stability of pro-
teins [10,11]. In addition, the identity of the amino-termi-
nal residue of a protein can dramatically affect its rate of
turnover by regulating its degradation by the N-end rule
pathway or other mechanisms [12–14]. A defect in initia-
tor methionine removal caused by MetAP2 inhibition
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therefore might lead to aberrant levels of proteins impor-
tant for cell proliferation.
All eukaryotes appear to have two MetAPs: MetAP1 and
MetAP2 [15,16]. Individual deletion of either MetAP
gene in Saccharomyces cerevisiae results in viable yeast with
a slow growth phenotype. Yeast in which both genes have
been disrupted are inviable, however, indicating that
MetAP activity is necessary for survival in eukaryotes [16].
As the growth of most mammalian cells and cell lines are
not substantially inhibited by TNP-470, it would appear
that, unlike yeast, most mammalian cells do not require
MetAP2 for growth. The basis of the selective inhibition
of endothelial cells by TNP-470 remains unclear. One
simple explanation would be that these cell types do not
express MetAP1, and therefore inactivation of MetAP2
results in complete loss of cellular MetAP activity. Alter-
natively, MetAP2-specific substrates essential for the
growth of drug-sensitive cells may exist that require
removal of the initiator methionine for proper activity or
stability. Proteins that inhibit the growth of these cells
may also be stabilized by retention of its initiator methion-
ine, leading to protein accumulation and cell-cycle arrest.
Here, we show that MetAP2 activity is inhibited in intact
cells by TNP-470 at concentrations that inhibit cell
growth. Furthermore, such inhibition is shown to result in
altered amino-terminal processing of a subset of cellular
proteins. These observations confirm the existence of spe-
cific MetAP2 substrates in vivo which cannot be effi-
ciently processed in the absence of the enzyme, indicating
that inhibition of MetAP2 by TNP-470 is a plausible
mechanism for effecting cell-cycle arrest.
Results
For inhibition of MetAP2 to mediate the growth inhibitory
effects of TNP-470 and ovalicin, the drugs must inactivate
the enzyme intracellularly when applied to intact cells at
concentrations that inhibit cell growth. To determine
whether this is the case, we employed a previously
described biotin–fumagillin conjugate which can be used to
detect unbound MetAP2 in cell extracts [8,9,17]. Bovine
aortic endothelial cells (BAECs) were treated for 72 hours
with varying concentrations of TNP-470 and were either
assayed for cell proliferation or lysed for determination of
unbound MetAP2. Lysates were treated with biotin-fumag-
illin, labeling MetAP2 protein that remained unbound fol-
lowing TNP-470 treatment. Samples were subjected to
sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS–PAGE) followed by blotting to nitrocellulose mem-
brane. Bound biotin was detected by probing the mem-
brane with streptavidin–horseradish peroxidase, and the
signal was competed by cell treatment with increasing con-
centrations of TNP-470 (Figure 1). A concentration of
100 ± 13 pM TNP-470 results in modification of half of the
MetAP2 in intact cells as determined using this assay. A
similar drug concentration (161 ± 69 pM) was found to
inhibit cell growth by 50%, indicating that inactivation of
MetAP2 in endothelial cells occurs at concentrations that
correlate with decreased proliferation. A similar correlation
was also obtained in BAECs using FOS-37 [8], an ovalicin
derivative with a 100-fold reduced potency (data not
shown). Inactivation of MetAP2 in endothelial cells there-
fore appears to occur at drug concentrations that result in
growth inhibition. 
Whereas primary endothelial cells are sensitive to TNP-
470 and ovalicin, many other cell types, including many
transformed cells, show resistance to the compounds
[3,18]. One possible explanation for this observation would
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Figure 1
Inhibition of cell proliferation correlates with inactivation of MetAP2 in
endothelial cells. (a) BAECs were pre-incubated in varying
concentrations of TNP-470 (tenfold dilutions from 500 nM to 0.5 pM)
for 24 h prior to lysis. Lysates were pre-cleared with immobilized
streptavidin and incubated with excess (10 µM) biotin–fumagillin (BF)
conjugate. Lysates were subjected to 8% SDS–PAGE and
transferred to nitrocellulose. BF-bound MetAP2 was visualized using
streptavidin-conjugated horseradish peroxidase (Strep-HRP) as
previously reported [8,17]. Total MetAP2 present in the lysate was
visualized by western blot. (b) The MetAP2 band from (a) was
quantitated using NIH Image 1.60 software and plotted with cell
proliferation as determined by incorporation of [3H]-thymidine.
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be that endothelial cells lack MetAP1, which would mean
that treatment with TNP-470 or ovalicin would result in
complete loss of MetAP activity in these cells. Cells would
thereby be unable to proliferate, by analogy with yeast
lacking MetAP1 [8]. To address this possibility, we exam-
ined expression levels of both MetAP1 and MetAP2 in a
series of human cell lines. Whereas human umbilical vein
endothelial cell (HUVEC) proliferation was potently
inhibited following ovalicin treatment, several other
human cells lines including HeLa, Jurkat T lymphocytes,
and HT1081C, a human fibrosarcoma cell line, showed a
proliferation decrease of only approximately 30%
(Figure 2). Western blotting of the cell extracts revealed
no significant differences in expression of MetAP1 or
MetAP2. Furthermore, similar concentrations of TNP-470
were shown to inactivate MetAP2 in drug-sensitive and
drug-insensitive cell types (data not shown). It is therefore
unlikely that TNP-470 treatment blocks all MetAP activ-
ity in sensitive cells or that the expression level of either
protein confers resistance in insensitive cell types.
Given that differences in expression of the two MetAP
enzymes did not appear to account for the cell-type speci-
ficity of the compound, we postulated that drug-sensitive
cells may have specific MetAP2 substrates that cannot be
processed by the type 1 enzyme. Several approaches were
therefore taken to determine whether cells treated with
the drugs have specific defects in methionine processing.
First, protein myristoylation was examined, as N-myris-
toylation requires the prior removal of the initiator
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Figure 2
Expression of MetAP1 and MetAP2 does not account for the cell-type
specificity of the compounds. (a) Sensitivity of human cell types to
ovalicin. Cells were incubated with indicated concentrations of ovalicin
for 32 h and pulsed with [3H]-thymidine for the final 8 h. (b) Western
blotting of cell extracts with MetAP1, MetAP2 and actin antibodies.
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Figure 3
Analysis of protein myristoylation in BAECs in the presence or absence
of TNP-470. Cells were pretreated with 50 nM TNP-470 or carrier
solvent alone as indicated for 48 h prior to labeling for 4 h with
[3H]-myristic acid. Extracts were resolved using SDS–PAGE (10%),
and lanes were treated with either 1 M Tris–HCl, pH 7.0, or 1 M
hydroxylamine, pH 7.0, as indicated prior to fluorography. The band of
~150 kDa molecular weight, which decreases upon TNP-470
treatment, is indicated with an arrow.
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methionine to expose an amino-terminal glycine residue.
BAECs were pretreated with TNP-470 and then labeled
with [3H]-myristic acid, which is metabolically converted
to myristoyl CoA and incorporated into proteins as
N-myristoyl groups [19]. Labeled cell extracts were sub-
jected to SDS–PAGE followed by fluorography. Samples
were run in duplicate and treated with either Tris buffer
or 1M hydroxylamine, which cleaves thioester bonds, to
ensure that the incorporated radioactivity was due to
myristoylation and not due to S-palmitoylation as a conse-
quence of metabolic conversion of the labeled myristate to
palmitate. A series of myristoylated protein bands could
be detected using this procedure (Figure 3). For most of
the detected proteins, no differences in the intensity of
labeling were observed between untreated cells and cells
treated with TNP-470. The only exception was a single
protein band of ~150 kDa molecular weight, which
decreased ~twofold in intensity upon treatment with
TNP-470. This band may correspond to endothelial nitric
oxide synthase (eNOS), which has recently been reported
to be affected by TNP-470 treatment [20]. To determine
whether the myristoylation of a subset of proteins that
could not be visualized by one-dimensional electrophore-
sis was affected by TNP-470 treatment, extracts were also
analyzed by two-dimensional electrophoresis, and no dif-
ferentially myristoylated proteins were detected (data not
shown). Though it is likely that there are scarce myristoy-
lated proteins that could not be detected by this method,
it would appear that for the great majority of proteins des-
tined for myristoylation MetAP1 can compensate in the
absence of MetAP2 activity.
Given the precedent for effects on turnover rate as a con-
sequence of changes in the amino terminus of a protein,
we also examined whether TNP-470 treatment affected
the half-life of cellular proteins. Cells were pre-treated
with TNP-470 or carrier solvent alone and then pulse
labeled with [35S]-methionine. Following the pulse, cells
were exchanged into fresh media containing excess cold
methionine and extracts were prepared at various times
thereafter. Extracts were analyzed using two-dimensional
electrophoresis followed by autoradiography to allow the
observation of as many proteins as possible. Despite detec-
tion of several rapidly degraded proteins (with half-lives of
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Figure 4
TNP-470 affects the migration of several protein spots by two-
dimensional electrophoresis. Cells were pretreated with either
(a) carrier solvent alone or (b) 50 nM TNP-470 for 4 h prior to pulse
labeling with [35S]-methionine. Extracts were prepared immediately
following the pulse and analyzed using two-dimensional
electrophoresis (NEPHGE/SDS–PAGE) followed by autoradiography.
Altered migration of protein spots of 55 kDa (top panels), 37 kDa
(middle panels), and 16 kDa (bottom panels) are shown. The 16 kDa
spot shifts to co-migrate with the spot immediately to its left upon
treatment with TNP-470.
– TNP-470 + TNP-470
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Figure 5
TNP-470 only affects the migration of the 37 kDa and 16 kDa proteins
synthesized subsequent to drug treatment. Cells were treated for 4 h
with either TNP-470 or carrier solvent alone as indicated prior to pulse
labeling with [35S]-methionine. Extracts were prepared either
immediately or 16 h following the pulse as indicated and analyzed by
two-dimensional electrophoresis followed by silver staining. (a) Altered
migration of the 37 kDa protein is visible by silver stain only at the 16 h
time point. (b) Migration of the 16 kDa protein is not visibly affected
over the course of 20 h of drug treatment.
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less than 16 hours), no clear differences in the turnover
rate of any protein were observed upon TNP-470 treat-
ment (data not shown). However, several protein spots,
which migrated with molecular weights of roughly 16 kDa,
37 kDa and 56 kDa, displayed altered mobility upon drug
treatment when visualized by autoradiography (Figure 4).
Interestingly, these changes in mobility were not evident
upon silver staining of extracts prepared immediately fol-
lowing the pulse. The mobility of the 37 kDa and 56 kDa
proteins when visualized by silver staining began to
change at later time points (20 hours after initiation of drug
treatment), whereas no change in migration was evident
for the 16 kDa protein during the same time period
(Figure 5 and data not shown). These observations sug-
gested that the altered mobility observed was due to modi-
fications that only occurred to protein molecules
synthesized subsequent to drug treatment. The ability to
detect a partial change in mobility of the 37 kDa and
56 kDa proteins by silver stain at later times probably indi-
cates that turnover of a detectable fraction of the protein
has occurred by that time.
To study these modifications further, the 37 kDa and
16 kDa proteins, which were relatively abundant as
judged by the intensity of silver staining, were identified
using matrix-assisted laser desorption ionization–time of
flight (MALDI–TOF) mass spectrometry analysis of in-
gel tryptic digests [21]. Mass spectra of tryptic peptides
from the 37 kDa protein revealed 16 peptides, which were
used to search the protein databank. Of the 16 masses,
nine matched predicted peptides from the enzyme glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) with
high accuracy (Table 1). Two additional peptides appear
to result from modification of GAPDH cysteine residues
with monomeric acrylamide. The nature of the remaining
five peptides is not known but may reflect allelic differ-
ences between the isolated protein and the sequence in
the protein databank or possibly unknown post-transla-
tional modifications. The mass spectrum from the tryptic
digest of the 16 kDa protein contained 12 peaks distinct
from background. Of these, 11 matched peptides derived
from the peptidyl prolyl cis–trans isomerase cyclophilin A,
including three that were modified by acrylamide as above
(Table 2). In addition, both protein assignments were con-
sistent with the observed molecular weights of 37 and
16 kDa, respectively.
Both bovine GAPDH and cyclophilin A have their initia-
tor methionine residues removed co-translationally to
yield mature proteins with unmodified valine residues at
their amino termini, raising the possibility that the shifts
in mobility following drug treatment are due to retention
of the initiator methionine. Furthermore, varying the
concentration of TNP-470 treatment confirmed that the
appearance of the altered form of GAPDH occurred at
drug concentrations comparable to those which were
found to inactivate MetAP2 in endothelial cells (data not
shown). To investigate this possibility, we chose to purify
GAPDH from cells treated with TNP-470. GAPDH was
chosen over cyclophilin A as its rate of turnover appeared
to be more rapid (Figure 5). BAECs were treated for
72 hours with either 50 nM TNP-470 or carrier solvent
alone, and extracts were prepared by hypotonic lysis.
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Table 2
Molecular weights of tryptic peptides from the 16 kDa protein
indicate it to be bovine cyclophilin A.
Measured Calculated Location in
mass (Da) mass (Da) Cyclophilin A peptide sequence
686.371 686.399 HVVFGK 125–130
737.349 737.358 TAENFR 31–36
777.341 777.347 GSCFHR 49–54*
1055.53 1055.541 VSFELFADK 19–27
1132.61 1132.604 KITIADCGQI 154–163*
1140.57 1140.558 FDDENFILKH 82–90
1379.79 1379.758 VSFELFADKVPK 19–30
1505.78 1505.746 VKEGMNIVEAMER 131–143
1564.76 – – –
1612.76 1612.761 IIPGFMCQGGDFTR 55–68*
1817.95 1817.896 SIYGEKFDDENFILK 76–90
1946.01 1946.002 VNPTVFFDIAVDGEPLGR 1–18
*Peptides predicted to be modified on cysteine residues by
monomeric acrylamide.
Table 1
Molecular weights of tryptic peptides from the 37 kDa protein
identify it as bovine GAPDH. 
Measured Calculated Location in 
mass (Da) mass (Da) GAPDH peptide sequence
783.344 – – –
795.426 795.425 LTGMAFR 225–231
806.397 – – –
977.55 977.542 KAITIFQER 70–77
1033.61 – – –
1213.58 – – –
1358.71 1358.681 VVDLMVHMASKE 321–332
1369.78 1369.744 GAAQNIIPASTGAAK 198–212
1461.87 1461.832 LEKPAKYDEIKK 246–257
1556.83 1556.811 VPTPNVSVVDLTCR 232–245
1570.88 1570.826 VPTPNVSVVDLTCR 232–245*
1615.93 1615.881 AITIFQERDPANIK 70-83
1763.83 – – –
1795.83 – – –
1848.01 1848.936 IVSNASCTTNCLAPLAK 143–159*
2213.08 2213.11 VIISAPSADAPMFVMGVNHEK 116–136
*Peptides predicted to be modified on cysteine residues by
monomeric acrylamide.
GAPDH was purified using affinity chromatography on
AMP agarose [22] (Figure 6a). As judged by immunoblot-
ting, TNP-470 treatment had little effect on levels of the
enzyme, and recovery from extracts of both drug-treated
and untreated cells was nearly quantitative (Figure 6b).
Two-dimensional gel analysis of the purified protein
from TNP-470-treated cells revealed an ~1:1 mixture of
the two closely migrating forms, whereas the material
from untreated cells was almost exclusively a single
species (Figure 6c). 
To confirm that this mobility shift resulted from alter-
ations at the amino-terminus of GAPDH, purified material
from both preparations was separated using SDS–PAGE
and electrophoretically transferred to PVDF membrane.
The amino-terminal sequences were subsequently deter-
mined by Edman degradation. The amino-terminal
sequence of the protein purified from untreated cells was
identical to the predicted sequence for bovine GAPDH,
with complete removal of the initiator methionine [23].
The protein from TNP-470-treated cells, however,
appeared to be a mixture of GAPDH with the methionine
retained and with the methionine removed in roughly
equal amounts (Table 3). This result establishes that com-
plete processing of the amino-terminal methionine from
GAPDH requires MetAP2 activity, and that this activity is
inhibited in intact cells by TNP-470. Taken together with
the observation that protein myristoylation is not generally
effected by the drug, this result indicates that the amino-
terminal processing of some, but not all, proteins is dimin-
ished in TNP-470 treated cells. It is formally possible,
however, that the defect in GAPDH processing was
simply due to an overall decrease in MetAP activity in
cells, which may have led to subtle decreases in myristoy-
lation not detected in our experiments. 
In order to observe directly whether MetAP2 was required
for complete amino-terminal methionine removal from all
proteins, we chose to examine the amino terminus of
another cytosolic protein. Bovine glutathione S-trans-
ferase-pi (GST-pi) is normally processed by removal of its
initiator methionine to produce a mature protein with an
unblocked amino-terminal proline residue [24]. We iso-
lated GST-pi from cells treated with or without 50 nM
TNP-470 using affinity chromatography on glutathione
sepharose. To ensure that the protein analyzed was syn-
thesized subsequent to drug treatment, cells were plated
at low density and allowed to grow to confluence under
both conditions. As TNP-470 decreases the growth rate of
BAECs dramatically, drug-treated cells did not reach con-
fluence until 7 days following replating, while carrier
treated cells reached confluence after only 2 days.
Western blotting confirmed that ~75% of the protein
present in extracts was synthesized during the last 6 days
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Figure 6
Purification of GAPDH from endothelial cells
treated with or without TNP-470. Cells were
treated for 72 h with 50 nM TNP-470 or
carrier solvent alone. GAPDH was isolated
from extracts by AMP-agarose affinity
chromatography. (a) Silver staining of purified
material. (b) Western blotting with GAPDH
antibodies. Equal portions of the extracts,
AMP-agarose bead supernatants, column
wash and 1 mM NAD+ elution fractions were
loaded in each lane. (c) Two-dimensional
electrophoresis of purified GAPDH from cells
treated with carrier solvent alone (left panel)
or TNP-470 (right panel).
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of drug treatment, as there was fourfold more GST-pi
present in equal proportions of extracts prepared 7 days
after initiating drug treatment compared with extract from
an identical plate prepared one day following drug treat-
ment (data not shown). Amino-terminal sequencing of the
purified protein revealed that approximately 80% of the
protein had its initiator methionine removed, whereas
~20% retained the methionine regardless of whether it
was from drug-treated or untreated cells (Table 4). This
result indicates that, in contrast with GAPDH, MetAP2
activity is dispensable for normal processing of GST-pi,
illustrating that specific MetAP2 substrates do exist within
endothelial cells.
To determine whether the substrate specificity observed
in vivo could be recapitulated in vitro, the activity of the
recombinant enzymes towards a series of model peptides
was examined. Recombinant human MetAP1 and
MetAP2 were produced and purified from baculovirus-
driven insect cells. As bovine cyclophilin A and GAPDH
are processed to reveal an amino-terminal valine and pro-
cessing of GST-pi reveals an amino-terminal proline
residue, it was possible that the identity of the second
translated residue was the basis for the observed speci-
ficity. To determine whether the specificity between the
two enzymes was based on the identity of the second sub-
strate residue, the activity of each enzyme was measured
using a series of peptides based on the amino terminus of
hemoglobin (MVHTLPEE; using single-letter amino-acid
code) differing at the second residue. In addition, the
activity of the enzymes towards peptides corresponding to
the amino termini of bovine eNOS, GAPDH, and GST-pi
were also examined. The activity of each enzyme was nor-
malized to that for the reference tetrapeptide substrate
Met–Gly–Met–Met to simplify interpretation, although
MetAP2 showed a 4.5-fold higher activity for this peptide
than did MetAP1. Both MetAP1 and MetAP2 showed
activity towards peptides that have a small, uncharged
second residue, as has been observed previously using
peptide substrates in other in vitro studies [16,25–27]
(Table 5). Although some differences were apparent
between the two enzymes, specificity appeared to be dic-
tated by more than simply the identity of second residue.
For example, the trend in relative activity between
MetAP1 and MetAP2 was not the same for the two pep-
tides that have a glycine residue in the second position.
Likewise, the presence of valine in the second position
could not be used to predict the relative ability of a
peptide substrate to be cleaved by MetAP1 versus
Research Paper  Methionine processing inhibited by TNP-470 and ovalicin Turk et al. 829
Table 3
Amino-terminal sequence analysis of GAPDH purified from
TNP-470-treated and untreated BAECs.
Literature TNP-470-treated
Cycle sequence Control cells cells
1 V V (44.1), M (0) V (13.6), M (17.0)
2 K K (47.7), V (0) K (19.1), V (10.6)
3 V V (42.2), K (3.0) V (15.7), K (17.0)
4 G G (34.3), V (2.0) G (17.2), V (12.2)
5 V V (36.7), G (2.4) V (16.4), G (14.8)
6 N N (23.1), V (4.8) N (9.9), V (13.5)
Purified GAPDH from TNP-470-treated cells was run on
SDS–PAGE, blotted to PVDF membrane, and sequenced by Edman
degradation. The picomolar amount of each amino acid is given for
each cycle in parentheses.
Table 4
Amino-terminal sequence of purified GST-pi from cells grown
to confluence in the presence or absence of TNP-470. 
Literature TNP-470-treated
Cycle sequence Control cells cells
1 P P (11.7), M (1.6) P (19.2), M (2.8)
2 P P (12.7) P (19.5)
3 Y Y (13.4), P (2.1) Y (20.5), P (3.8)
4 T T (9.7), Y (3.3) T (14.1), Y (5.5)
5 I I (13.6), T (1.9) I (22.8), T (3.3)
6 V V (10.8), I (2.8) V (17.6), I (5.9)
GST-pi isolated from BAECs treated with or without TNP-470 was
electrophoresed, blotted onto PVDF membrane and sequenced by
Edman degradation. The molar amount of each amino acid present in
each cycle is indicated.
Table 5
Comparison of substrate specificity of human MetAP1 and
MetAP2. 
Human MetAP1 Human MetAP2
Peptide relative activity (%) relative activity (%)
MGMM 100 ± 6 100 ± 4
MGHTLPEE 100 ± 7 14 ± 5
MAHTLPEE 530 ± 15 79 ± 5
MPHTLPEE 260 ± 10 76 ± 6
MVHTLPEE (hemoglobin) 185 ± 8 63 ± 6
MSHTLPEE 93 ± 8 39 ± 5
MTHTLPEE 93 ± 8 38 ± 5
MLHTLPEE 0* 0*
MFHTLPEE 0* 0*
MDHTLPEE 0* 0*
MRHTLPEE 0* 0*
MGNLKSVG (eNOS) 54 ± 6 152 ± 8
MPPYTIVY (GST-pi) 62 ± 8 63 ± 6
MVKVGVNG (GAPDH) 0* 25 ± 5
Enzyme activity was determined under standard assay conditions using
peptide substrates at a final concentration of 2 mM. The activity of
each enzyme was normalized to that for the reference substrate
Met–Gly–Met–Met. Data reported as mean activity ± S.D. *No
detectable cleavage.
MetAP2. Interestingly, the specificity observed for the
bovine proteins in vivo could be reconstituted in vitro
using the corresponding amino-terminal peptides. When
the activities of MetAP1 and MetAP2 towards these
peptide substrates were directly compared without the
normalization factor, peptides corresponding to both
eNOS and GAPDH showed strong preferences for cleav-
age by MetAP2 (> tenfold), whereas the peptide based on
GST-pi showed only a modest preference for MetAP2
cleavage. The observed in vivo specificity of MetAP2
therefore can be recapitulated with recombinant protein in
an in vitro system, paving the way for the future investiga-
tion of the rules governing substrate specificity for this
class of enzymes.
Discussion
Recent reports have identified MetAP2 as a cellular target
for a class of small-molecule angiogenesis inhibitors struc-
turally related to the natural product fumagillin [8,9]. Inhi-
bition of MetAP2 aminopeptidase activity could result in
growth inhibition by blocking the activity of key polypep-
tide substrates required for cell proliferation. Given that
MetAP2 appears to be a ubiquitously expressed house-
keeping enzyme, however, this model must account for
the known selectivity of this class of compounds for
endothelial cells [3,18]. One simple explanation would be
that sensitive cell types lack the related type-1 enzyme,
whereas in drug-insensitive cell types MetAP1 compen-
sates for the loss of MetAP2 activity. This situation has
been observed in yeast strains lacking MetAP1 [8,9]. Sur-
prisingly, expression levels of the two enzymes showed no
significant differences in sensitive and resistant cell types,
arguing against this model. In drug-sensitive mammalian
cell types, unlike in yeast, MetAP1 activity therefore
cannot compensate for the loss of MetAP2 aminopepti-
dase activity. In addition, the observation that similar con-
centrations of TNP-470 were required to inactivate
MetAP2 in intact cells regardless of cell sensitivity to the
compounds argues against differential drug permeability
or metabolism in drug-insensitive cells. Factors that affect
cell sensitivity to TNP-470 therefore appear to act subse-
quent to the inactivation of MetAP2. 
Another model to account for cell-type selectivity of the
compounds postulates the existence of MetAP2-specific
substrates in drug-sensitive cells that are important for
proliferation. However, no MetAP2-specific substrates
had yet been identified prior to this study, and work with
yeast deficient in either enzyme revealed that these two
enzymes are largely redundant. Examination of protein
myristoylation provided data consistent with a largely
overlapping specificity for these enzymes. With a single
exception, detectable protein N-myristoylation remains
unaffected in TNP-470-treated cells, indicating that
MetAP1 activity can largely compensate for MetAP2. It
was recently reported that myristoylation of eNOS is
decreased twofold in BAECs treated with TNP-470 [20].
However, high concentrations (5 µM) of the drug, which
correlated with cytotoxicity rather than growth arrest, were
used in this study, raising the possibility that inhibition of
eNOS myristoylation (and cell death) may have resulted
from nonspecific effects such as inhibition of MetAP1 as
well as MetAP2. The molecular weight of eNOS is consis-
tent with the protein observed in our experiments and a
peptide based on the eNOS amino terminus shows a
strong preference for MetAP2, indicating the possibility
that eNOS myristoylation in cells is hampered by specific
inhibition of MetAP2. Experiments to examine this possi-
bility are currently underway.
Other proteins affected by TNP-470 treatment were iden-
tified using two-dimensional gel electrophoresis of cell
extracts pulse-labeled with [35S]-methionine following
drug treatment. Although no changes were observed in
the half-lives of detectable proteins, drug treatment
resulted in changes in the migration of several newly syn-
thesized proteins. Two of these proteins were identified,
using mass spectrometry, as GAPDH and cyclophilin A.
Purification and sequencing of GAPDH from cells treated
with TNP-470 revealed partial retention of the initiator
methionine compared with untreated cells. Although only
half of the GAPDH isolated from drug-treated cells had
failed to undergo amino-terminal processing, the fraction
of the enzyme with altered mobility by two-dimensional
electrophoresis appears closer to 70% when examined by
autoradiography, a ratio that reflects the constitution of
protein synthesized only during the pulse period when
MetAP2 activity was absent (see Figure 4). A portion of
the protein isolated was therefore likely to be present
prior to drug treatment, indicating that an even smaller
fraction the protein (~30%) synthesized in the absence of
MetAP2 activity undergoes methionine removal. In con-
trast, TNP-470 treatment had no effect on initiator
methionine cleavage of GST-pi, confirming that methion-
ine retention is not simply due to an overall decrease in
cellular MetAP activity. GAPDH therefore represents, to
our knowledge, the first demonstration of a MetAP2-spe-
cific substrate in vivo and the first direct demonstration
that TNP-470 treatment of cells results in amino-terminal
processing defects.
Using recombinant human MetAP1 and MetAP2 with
methionine-containing peptides as substrates, we gained
significant, albeit incomplete, insight into the substrate
specificity for this class of enzymes. The two types of
amino-terminal methionine-processing enzymes appear to
have distinct substrate specificity (Table 5). Whereas
MetAP1 prefers alanine, proline and valine, MetAP2
favors glycine, alanine and proline as the second residue. It
will be critical in the future to elucidate the rules govern-
ing substrate specificity for this class of enzymes. Impor-
tantly, we have shown in this study that the specificity
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observed in vivo can apparently be reconstituted in an in
vitro system using recombinant enzymes. In addition,
specificity in the in vitro system appeared to be dictated by
sequence determinants as well as by the first two amino-
terminal residues as shown by the dramatic decrease in
activity of MetAP2 towards MGHTLPEE in comparison
with MGMM (Table 5). This situation is probably the case
in vivo as well; whereas all N-myristoylated proteins are
processed to reveal an amino-terminal glycine residue,
only a single detectable myristoylated protein was affected
by TNP-470 treatment of endothelial cells. On the basis of
the crystal structures of MetAPs from Escherichia coli to
human, the putative substrate-binding pocket in MetAPs
are relatively shallow, fitting about two amino acid
residues [28,29]. The additional interaction between sub-
strates and MetAPs would have to result from interactions
with residues on MetAP surfaces around the binding
pocket. A more comprehensive study of the sequence
determinants of specificity for this class of enzymes will be
required to reveal the basis of this specificity between
MetAP1 and MetAP2.
Given the nature of our approach to identify MetAP2-spe-
cific substrates, we have identified only relatively abun-
dant cellular proteins. Drug-induced defects in GAPDH
or cyclophilin A processing are not likely to play any direct
role in the inhibition of cell proliferation by TNP-470.
The time required to accumulate substantial amounts of
the altered forms of these proteins is inconsistent with the
rapid growth arrest observed in drug-treated cells [30].
Additionally, TNP-470 treatment does not affect cellular
GAPDH activity (data not shown). Other more relevant
MetAP2-specific substrates probably remain below the
limits of detection for the methods used in this study, and
it is not known at this time what fraction of cellular pro-
teins are specifically processed by MetAP2. Crucial com-
ponents to the understanding of the mechanism of action
of TNP-470 and ovalicin will be the future identification
of these specific MetAP2 substrates and the rules that
govern MetAP1 and MetAP2 specificity in vivo. 
Significance
TNP-470, a synthetic derivative of the natural product
fumagillin, acts as a potent inhibitor of angiogenesis and
endothelial cell proliferation. The compound is currently
being evaluated in clinical trials for treatment of a
variety of cancers. Recently, this class of compounds has
been found to inhibit the type 2 methionine aminopepti-
dase (MetAP2) in vitro, and structure–activity relation-
ships suggest that MetAP2 inhibition mediates the
anti-angiogenic effects of this class of compounds. Here,
we have found that concentrations of TNP-470 suffi-
cient to inactivate MetAP2 in intact endothelial cells are
comparable to drug concentrations that inhibit cell prolif-
eration, providing further evidence that inhibition of
MetAP2 accounts for the ability of TNP-470 to block
cell growth. Moreover, we have shown that amino-termi-
nal processing defects occur in cells treated with
TNP-470, demonstrating inhibition of MetAP activity in
intact cells. This effect was specific for a subset of cellu-
lar proteins, providing the first demonstration of in vivo
specificity between MetAP1 and MetAP2. One cellular
MetAP2 substrate affected by TNP-470 treatment was
identified as glyceraldehyde-3-phosphate dehydrogenase,
resulting in a detectable mobility shift by two-dimen-
sional gel electrophoresis. This mobility shift now pro-
vides a novel in vivo assay for MetAP2 inhibition, which
should aid in the development of specific MetAP2
inhibitors as angiogenesis inhibitors. As amino-terminal
processing is known to be required for the proper func-
tion of some cellular proteins, this work renders plausi-
ble a mechanism for growth inhibition by TNP-470 as a
consequence of initiator methionine retention, leading to
the inactivation of as yet unidentified proteins that are
essential for endothelial cell growth.
Materials and methods
[Methyl-3H]-Thymidine, EXPRESS [35S]-methionine/cysteine mixture,
[γ-32P]-ATP, and ENHANCE fluorographic enhancer were purchased
from DuPont/NEN Life Science. [9,10(n)-3H]-myristic acid was
obtained as an ethanolic solution from Amersham and was concen-
trated to dryness and resuspended to 10 mCi/ml in EtOH prior to use.
Antibodies to GAPDH and GST-pi were obtained from Biodesign Inter-
national and Medical and Biological Laboratories (Nagoya), respec-
tively. Antibodies to actin were obtained from Boehringer Mannheim.
Polyclonal antibodies against MetAP2 have been reported previously
[8] and those against MetAP1 were generated in a similar fashion
(Y-H.C., unpublished observations).
Cell culture
Cells were grown in a humidified incubator at 37°C in an atmosphere of
5% CO2. Human umbilical vein endothelial cells (HUVECs) and bovine
aortic endothelial cells (BAECs) were obtained from Clonetics and cul-
tured in EGM-2 and EGM-MV (Clonetics), respectively. HT1081C cells
were cultured in DME containing 10% fetal bovine serum (FBS) and
50 units/ml penicillin plus 50 µg/ml streptomycin (P/S).
Cell proliferation assay
Cells prepared as described above were seeded into 96-well plates
and grown in the presence of drug or carrier alone (0.5% EtOH) for
32 h. Cells were pulsed with [3H]-thymidine (6.7 Ci/mmol, 1 µCi per
well) for the final 8 h of culture and harvested with a semi-automated
cell harvester onto glass fiber papers for scintillation counting.
Electrophoresis
SDS–PAGE was performed as described by Laemmli [31], using 2%
SDS, 50 mM Tris HCl, pH 6.8, 5% β-mercaptoethanol, with 0.1% bro-
mophenol blue as loading buffer. Isoelectric focusing (IEF) and non-
equilibrium pH gradient electrophoresis (NEPHGE) were performed as
described previously [32,33], except that ampholytes used were pur-
chased from Bio-Rad Laboratories. For IEF, samples were made up to
1% SDS with 20 mM dithiothreitol (DTT), heated in a boiling water
bath for 3 min, and cooled to ambient temperature after which 1/10th
volume of two-dimensional gel loading buffer (9 M urea, 4% CHAPS,
1% DTT, 2% ampholytes, pH 3–10) was added.
In vivo binding assay
BAECs were incubated in varying concentrations of TNP-470 (tenfold
dilutions from 500 nM to 0.5 pM) or EtOH carrier (0.1% final) for
24 h. Cells were harvested or pulsed for 8 h with [3H]-thymidine to
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measure cell proliferation. BAECs (10 cm plate) were washed twice
with cold PBS and lysed in 500 µl lysis buffer (0.2% Triton X-100,
20 mM Tris–HCl, pH 7.2, 100 mM KCl, 1 mM PMSF, 200 µg/ml apro-
tinin, 25 µM leupeptin, and 10 µg/ml pepstatin A). Lysates were incu-
bated at 4°C for 10 min and centrifuged at 16,000 × g for 10 min to
remove cell debris. Samples were pre-cleared by adding 25 µl of pre-
equilibrated immobilized streptavidin beads (Boehringer Mannheim)
and mixing at 4°C for 1 h. Samples were normalized for protein con-
centration, diluted in lysis buffer to 1 mg/ml, and incubated with
biotin–fumagillin (10 µM) or EtOH carrier alone (0.5% final) for 2 h at
4°C. Samples were subjected to SDS–PAGE, transferred to nitrocel-
lulose, and blotted with streptavidin-horseradish peroxidase or anti-
MetAP2 antibodies as previously described [8].
Analysis of protein myristoylation
BAECs were trypsinized from confluent monolayers, seeded into fresh
plates (105 cells/cm2), and allowed to recover 4 h at 37°C. After drug or
EtOH carrier treatment for the indicated time, the media was removed
and replaced with labeling media (DME with low glucose, 5% dialyzed
FBS, and 5 mM sodium pyruvate) containing drug or carrier. [3H] myris-
tic acid (54 Ci/mmol, 10 mCi/ml in EtOH) was added to a final concen-
tration of 50 µCi/ml, and cells were incubated for the indicated times.
After washing once with PBS, cells were harvested by direct lysis into
either SDS–PAGE loading buffer or two-dimensional gel loading buffer.
Extracts were incubated at room temperature for 2 h, frozen on dry
ice/EtOH and stored at –20°C until analysis by either one- or two-
dimensional gel electrophoresis as described above. Gels were stained
with Coomassie blue, impregnated with an autoradiography enhancer
(NEN Enhance), dried, and exposed to X-ray film to visualize spots.
Analysis of total protein synthesis and turnover
BAECs were plated into 6-well dishes and grown to 50% confluence.
Cells were treated for 4 h with TNP-470 (50 nM) or EtOH carrier alone
(0.5 %), at which time the media was removed and replaced with label-
ing media (methionine-free DME containing 5% dialyzed FBS, 1 ml).
After incubating 10 min at 37°C, the media was replaced with fresh
labeling media (0.5 ml) containing 0.5 mCi/ml [35S] methionine (NEN
EXPRESS label, > 1000 Ci/mmol) including TNP-470 or carrier. Cells
were incubated 30 min at 37°C, washed once with complete media,
and then cultured in fresh complete media for various times. Cells were
washed with PBS and harvested directly into 150 µl two-dimensional
gel loading buffer either immediately or at 1 h, 4 h or 16 h following the
pulse. Extracts were kept at room temperature 1 h, frozen on dry ice
EtOH, and stored at –20°C until analysis by two-dimensional gel elec-
trophoresis (NEPHGE/SDS–PAGE). Gels were silver stained, dried
and exposed to BioMax film.
Mass spectrometry
Samples were prepared from silver-stained polyacrylamide gels
and analyzed using MALDI–TOF mass spectrometry as previously
described [8,21].
Purification of GAPDH for amino-terminal sequence analysis
BAECs were plated at 1/3 confluence and treated with either 50 nM
TNP-470 or 0.1% EtOH carrier alone in 15 cm plates (six of each type)
for 72 h. Cells were detached by treating with 1 mM EDTA in PBS, pel-
leted, washed once with PBS, and lysed by homogenization in three
packed cell volumes of hypotonic buffer (10 mM Tris HCl, pH 7.9,
1.5 mM MgCl2, 10 mM KCl, 1 mM PMSF, 1 mM DTT, 200 µg/ml apro-
tinin, 25 µM leupeptin and 10 µg/ml pepstatin A). Lysates were cen-
trifuged at 16,000 × g for 10 min at 4°C. Supernatants were dialyzed
for 18 h with one change into dialysis buffer (30 mM sodium phos-
phate, pH 6.0, 1 mM DTT and 1 mM EDTA). Samples were assayed for
protein by Bradford assay (Bio Rad), and 1 mg of protein was brought
to a volume of 2 ml with dialysis buffer and added to 0.35 ml of AMP-
agarose beads. Samples were rotated at 4°C for 20 h. The bead sus-
pensions were transferred to columns, drained, washed with
five column volumes of dialysis buffer, and then eluted with four 350 µl
portions of elution buffer (30 mM sodium phosphate, pH 7.5, 1 mM
DTT, 1 mM EDTA and 1 mM NAD+). Eluates were concentrated to
125 µl under reduced pressure, and then subjected to SDS–PAGE.
Samples were transferred to PVDF membrane in 10 mM CAPS, pH 11,
10% MeOH at 20 V for 2 h at 4°C. The membrane was stained with
Ponceau S (0.2% in 1% HOAc) and destained with ddH2O. Bands
were excised and submitted to the MIT Biopolymers laboratory for
sequence analysis.
Purification of GST-pi for amino-terminal sequence analysis
BAECs were plated at low density (20% confluence) and allowed to
grow to confluence in the presence or absence of 50 nM TNP-470.
Cells treated with TNP-470 were exchanged into fresh media contain-
ing drug after 3 days. Cells were washed once with cold PBS and then
extracted into lysis buffer (0.5% Triton X-100, 50 mM HEPES, pH 7.3,
250 mM NaCl, 1 mM DTT, 1 mM EDTA, 1 µg/ml aprotinin, 25 µM leu-
peptin, 1 mM PMSF, 1 ml per 15 cm plate) by scraping into a micro-
centrifuge tube and rotating at 4°C for 30 min. Extracts were
centrifuged 10 min at 16,000 × g at 4°C to remove debris, frozen on
dry ice/EtOH, and stored at –80°C until use. To purify GST, 1.2 ml of
each lysate was mixed with 100 µl of glutathione Sepharose 4B (Phar-
macia) for 2 h at 4°C. Beads were pelleted and washed three times for
5 min at 4°C with lysis buffer, suspended in SDS–PAGE loading buffer,
and heated in a boiling water bath for 10 min. Samples were prepared
for N-terminal analysis as described above for GAPDH, except that
blots were stained with Coomassie Brilliant Blue (0.1% in 1% HOAc,
40% MeOH) to visualize protein bands.
Peptide synthesis
Peptides were synthesized at the MIT Combinatorial Peptide Synthe-
sis Core Facility on an Applied Biosystems automated peptide synthe-
sizer using standard Fmoc chemistry. Peptides were purified by
preparative reversed phase HPLC and characterized by electrospray
mass spectrometry.
MetAP assay
Recombinant human MetAP2 was expressed and purified as previously
described [17]. Human MetAP1 was PCR-amplified from a cDNA
clone (KIAA0094, accession #: D42084) using a 5′ primer (5′-GATC-
GAATTCATGGCGGCCGTGGAGACG) tagged with an EcoRI site
(italicized) and a 3′ primer (5′-GATCCTCGAGTTAAAATTGAGACA-
TGAAGTGAGGCCG) tagged with an XhoI site (italicized). The
product was digested and ligated into pFastBac HTa (Gibco/BRL).
Recombinant protein was generated by analogous procedures as for
MetAP2. MetAP assays were performed as in Griffith et al. [17] using
peptide substrates at a final concentration of 2 mM. Released methion-
ine was quantitated according to the method of Zuo et al. [34].
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